LAWRENCE DONEHOWER to Neoplasms, Experimental
This is a "connection" page, showing publications LAWRENCE DONEHOWER has written about Neoplasms, Experimental.
Connection Strength
2.489
-
The utility of genetically altered mouse models for cancer research. Mutat Res. 2005 Aug 25; 576(1-2):1-3.
Score: 0.234
-
Probing p53 biological functions through the use of genetically engineered mouse models. Mutat Res. 2005 Aug 25; 576(1-2):4-21.
Score: 0.234
-
Cooperativity of p19ARF, Mdm2, and p53 in murine tumorigenesis. Oncogene. 2003 Oct 30; 22(49):7831-7.
Score: 0.206
-
Is p53 haploinsufficient for tumor suppression? Implications for the p53+/- mouse model in carcinogenicity testing. Toxicol Pathol. 2001; 29 Suppl:147-54.
Score: 0.169
-
The nature of the heterozygous Trp53 knockout model for identification of mutagenic carcinogens. Toxicol Pathol. 2001; 29 Suppl:24-9.
Score: 0.169
-
Increased tumor cell proliferation in murine tumors with decreasing dosage of wild-type p53. Mol Carcinog. 1999 Mar; 24(3):197-208.
Score: 0.149
-
Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. EMBO J. 1998 Aug 17; 17(16):4657-67.
Score: 0.144
-
Murine tumor suppressor models. Mutat Res. 1998 May 25; 400(1-2):391-407.
Score: 0.141
-
The p53-deficient mouse: a model for basic and applied cancer studies. Semin Cancer Biol. 1996 Oct; 7(5):269-78.
Score: 0.126
-
Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. Biochim Biophys Acta. 1996 Mar 18; 1242(3):171-6.
Score: 0.121
-
Effects of genetic background on tumorigenesis in p53-deficient mice. Mol Carcinog. 1995 Sep; 14(1):16-22.
Score: 0.117
-
A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nat Genet. 1995 Mar; 9(3):305-11.
Score: 0.113
-
Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nat Genet. 1993 Nov; 5(3):225-9.
Score: 0.103
-
Genetic background alters the spectrum of tumors that develop in p53-deficient mice. FASEB J. 1993 Jul; 7(10):938-43.
Score: 0.101
-
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992 Mar 19; 356(6366):215-21.
Score: 0.092
-
Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One. 2010 Jun 07; 5(6):e10995.
Score: 0.081
-
Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci U S A. 1998 Dec 22; 95(26):15608-12.
Score: 0.037
-
PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 2018 11 01; 23(5):700-713.e6.
Score: 0.036
-
The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2. Proc Natl Acad Sci U S A. 1996 Nov 26; 93(24):14106-11.
Score: 0.032
-
The role of p53 loss in genomic instability and tumor progression in a murine mammary cancer model. Prog Clin Biol Res. 1996; 395:1-11.
Score: 0.030
-
Transgenic mouse models for tumour-suppressor genes. J Intern Med. 1995 Sep; 238(3):233-8.
Score: 0.029
-
Synergistic induction of centrosome hyperamplification by loss of p53 and cyclin E overexpression. Oncogene. 2000 Mar 23; 19(13):1635-46.
Score: 0.010
-
Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. Mol Cell Biol. 1995 Aug; 15(8):4249-59.
Score: 0.007
-
Transgenic animals in toxicology. Fundam Appl Toxicol. 1994 Jan; 22(1):8-19.
Score: 0.007